EMT activates ER-to-Golgi trafficking through upregulation of REEP2 to promote lung cancer progression

This study identifies REEP2 as a critical mediator of lung cancer progression, demonstrating that the EMT activator ZEB1 upregulates REEP2 via miR-183 and miR-193a to enhance ER-to-Golgi trafficking, thereby promoting tumor growth, metastasis, and immunosuppression through the secretion of pro-tumorigenic factors.

The Gist

The Big Picture: A Cancer Cell's "Delivery Service"

Imagine a cancer cell as a busy factory. To grow, spread, and hide from the body's immune system (the security guards), this factory needs to ship out a lot of packages. These packages are proteins and signals that tell other cells to move, stop fighting, or help the cancer grow.

This paper discovers a specific delivery truck driver inside lung cancer cells that is essential for this process. The driver is a protein called REEP2. Without this driver, the cancer factory can't ship its packages, and the cancer struggles to spread.

The Story in Three Acts

Act 1: The "Switch" Turns On the Delivery Service

Lung cancer often goes through a transformation called EMT (Epithelial-to-Mesenchymal Transition). Think of this as the cancer cell changing its disguise. It stops being a stationary brick in a wall and turns into a slippery, moving slug that can crawl through the body.

When the cell makes this switch, a master control knob called ZEB1 gets turned on. ZEB1 is like a factory manager who decides, "We need to ship more packages now!"

However, the factory has a security system that usually keeps the delivery trucks (REEP2) locked in the garage. This security system uses tiny "stop signs" called microRNAs (specifically miR-183 and miR-193a) to block the trucks.

The Trick: The manager (ZEB1) sneaks in and rips up the "stop signs" (the microRNAs). Suddenly, the delivery trucks (REEP2) are free to drive out.

Act 2: The Traffic Jam at the Loading Dock

Once the trucks are free, they need to get to the right place. Inside the cell, there is a "Loading Dock" (the Endoplasmic Reticulum or ER) where packages are made, and a "Sorting Center" (the Golgi) where they are organized before being sent out.

Normally, the Loading Dock and the Sorting Center are far apart. It's like having a factory in New York and a post office in California; shipping takes forever.

The Magic: The newly freed delivery driver (REEP2) acts like a magnetic bridge. It physically pulls the Loading Dock right next to the Sorting Center. Now, the packages don't have to travel far; they can jump straight from the factory floor to the sorting center.

This creates a super-highway for the cancer cell. It can now flood the body with "pro-cancer" packages much faster than before.

Act 3: The Smokescreen

What's inside these packages?

1. Growth Signals: Things that tell the cancer to multiply.
2. Immune Evasion: The most dangerous part. The cancer ships out a specific protein called ATX.

Think of ATX as a smokescreen generator. When the cancer releases ATX, it attracts a group of "bad guys" called MDSCs (Myeloid-Derived Suppressor Cells). These are immune cells that usually fight cancer, but ATX tricks them into turning off their weapons and helping the cancer instead.

Meanwhile, the good immune cells (the T-cells, which are the body's elite soldiers) get confused and can't find the cancer.

The Result: Why This Matters

The researchers tested this by removing the delivery driver (REEP2) from the cancer cells.

• Without REEP2: The Loading Dock and Sorting Center stayed far apart. The packages got stuck. The cancer couldn't ship its "smokescreen" or growth signals.
• The Outcome: The cancer stopped growing, stopped spreading to other parts of the lung, and the body's immune system was able to fight it off effectively.

The Takeaway for Patients and Doctors

This paper identifies REEP2 as a critical weak spot in aggressive lung cancer.

• The Problem: Aggressive lung cancers use this "ZEB1 → REEP2 → Super-Highway" system to spread and hide.
• The Solution: If doctors can find a way to block REEP2 (or the bridge it builds), they could stop the cancer from shipping its dangerous packages. This would stop the cancer from spreading and might allow the patient's own immune system to win the battle.

In short: The cancer uses a specific protein (REEP2) to build a super-fast delivery line that helps it grow and hide. If we can cut the line, the cancer loses its power.

Technical Summary

1. Problem Statement

While membrane trafficking is known to be dysregulated in cancer, the specific mechanisms by which Epithelial-to-Mesenchymal Transition (EMT) reprograms trafficking pathways to drive lung adenocarcinoma (LUAD) progression and immunosuppression remain poorly understood. Specifically, there is a lack of knowledge regarding:

• Which specific membrane trafficking regulators are critical for EMT-driven metastasis under immune surveillance.
• How EMT transcription factors coordinate the physical transport of secretory cargoes from the Endoplasmic Reticulum (ER) to the Golgi apparatus.
• The downstream consequences of this trafficking on the Tumor Microenvironment (TME), particularly regarding immunosuppression.

2. Methodology

The study employed a multi-faceted approach combining in vivo screening, molecular biology, live-cell imaging, and proteomics:

• CRISPRi In Vivo Screen: The authors transduced a CRISPR interference (CRISPRi) library targeting 2,099 membrane trafficking genes into murine mesenchymal LUAD cells (344SQ, high ZEB1 expression). These cells were injected into syngeneic, immunocompetent mice to identify regulators essential for tumor growth under immune pressure.
• Genetic Manipulation:
  • Knockout/Knockdown: CRISPR/Cas9 was used to generate REEP2 knockout (KO) 344SQ cells. siRNA was used to deplete REEP2 in human LUAD lines (H1299, HCC827).
  • Overexpression: Inducible ZEB1 expression systems were used in epithelial cells (H322, HCC827) to mimic EMT.
• Mechanistic Validation:
  • miRNA Regulation: Luciferase reporter assays with wild-type and mutant 3'-UTRs of REEP2 were used to validate binding sites for miR-183 and miR-193a.
  • Live-Cell Imaging: Confocal microscopy tracked the colocalization of ER Exit Sites (ERES, marked by SEC16A/SEC24D) and the Golgi (marked by GM130).
  • Trafficking Kinetics: The RUSH (Retention Using Selective Hooks) system was used to quantitatively monitor the release of cargo (CD-MPR) from the ER to the Golgi. The VSV-G temperature-sensitive assay measured secretory trafficking to the plasma membrane.
• Secretome and Immune Profiling:
  • LC-MS/MS: Liquid chromatography-mass spectrometry analyzed conditioned media (CM) to identify REEP2-dependent secreted factors.
  • Flow Cytometry: Immune cell profiling of flank tumors in mice to quantify T cells, Myeloid-Derived Suppressor Cells (MDSCs), and macrophages.
• Clinical Correlation: Analysis of The Cancer Genome Atlas (TCGA) and TNMplot databases to correlate REEP2 expression with EMT signatures, patient survival, and immune infiltration.

3. Key Contributions

• Identification of REEP2: The study identifies REEP2 (Receptor Expression-Enhancing Protein 2), an ER-shaping protein, as a critical, previously unrecognized effector of the EMT-driven membrane trafficking program.
• Novel Regulatory Axis: It elucidates a specific molecular axis: ZEB1 $\rightarrow$ miR-183/miR-193a $\rightarrow$ REEP2. ZEB1 represses these microRNAs, thereby relieving the silencing of REEP2 mRNA.
• Mechanism of Action: The paper demonstrates that REEP2 physically recruits ERES to the Golgi apparatus, facilitating the efficient transport of secretory cargoes. This is distinct from general ER shaping; it specifically couples the ER exit site to the Golgi.
• Link to Immunosuppression: The study connects this trafficking mechanism to the secretion of pro-tumorigenic factors (specifically Autotaxin/ATX) that recruit MDSCs and suppress CD8+ T cells, creating an immunosuppressive TME.

4. Key Results

• Screening and Validation:

  • The in vivo CRISPRi screen identified REEP2 as a top hit required for tumor growth in immunocompetent mice.
  • REEP2 depletion significantly reduced orthotopic tumor size, metastasis to the mediastinum/contralateral lung, and cell proliferation/migration in mesenchymal LUAD cells, but had negligible effects on epithelial cells or non-cancerous bronchial cells.
  • High REEP2 expression correlates with poor prognosis and shorter survival in LUAD patients (TCGA data).

• ZEB1-miRNA-REEP2 Axis:

  • ZEB1 expression positively correlates with REEP2 levels.
  • ZEB1 suppresses miR-183 and miR-193a, which normally target the REEP2 3'-UTR.
  • Mutating the miRNA binding sites on the REEP2 3'-UTR abolished the repressive effect of these miRNAs, confirming direct regulation.

• Trafficking Mechanism:

  • In mesenchymal cells (high ZEB1/REEP2), ERES (SEC16A/SEC24D) show high colocalization with the Golgi (GM130).
  • Depleting ZEB1 or REEP2 disrupts this colocalization, causing ERES to disperse away from the Golgi.
  • RUSH Assay: REEP2 depletion drastically slowed the trafficking of CD-MPR cargo from the ER to the Golgi (reduced signal at 10 and 30 mins post-biotin).
  • VSV-G Assay: REEP2 depletion reduced the rate of VSV-G transport to the plasma membrane.

• Secretome and TME Remodeling:

  • LC-MS of conditioned media revealed that REEP2 depletion reduced the secretion of immunomodulatory and migratory factors, most notably Autotaxin (ATX).
  • ATX levels in the media were significantly reduced upon REEP2 knockdown, while intracellular ATX remained unchanged.
  • Immune Profiling: Tumors with REEP2 depletion showed increased infiltration of total CD8+ T cells and decreased MDSCs and naïve CD8+ T cells.
  • Clinical data (TIMER2.0) confirmed that high REEP2 expression correlates with higher MDSC and Treg infiltration in human LUAD.

5. Significance

• Therapeutic Vulnerability: The study reveals that mesenchymal LUAD cells are uniquely dependent on the REEP2-mediated trafficking pathway for their aggressive phenotype and immune evasion. This suggests REEP2 is a potential therapeutic target specifically for EMT-driven, metastatic lung cancer.
• Mechanistic Insight: It provides a concrete structural mechanism (ERES-Golgi coupling via REEP2) by which EMT transcription factors (ZEB1) rewire cellular logistics to support metastasis.
• Immunotherapy Resistance: By linking membrane trafficking to the secretion of factors that recruit MDSCs, the paper explains a mechanism of acquired resistance to immune checkpoint inhibitors (ICIs). Targeting this pathway could potentially re-sensitize tumors to immunotherapy.
• Broader Context: It expands the understanding of REEP family proteins beyond their known roles in hereditary spastic paraplegia (neuronal maintenance) to a critical role in cancer biology and secretory pathway regulation.